IFNG polymorphisms are associated with gender differences in susceptibiligy to multiple sclerosis

Genes and Immunity

Volumn 6, Issue 2, 2005, Pages 153-161

  Kantarci, O H ^a   Goris, A ^b   Hebrink, D D ^a   Heggarty, S ^c   Cunningham, S ^c   Alloza, I ^c   Atkinson, E J ^a   de Andrade, M ^a   McMurray, C T ^a   Graham, C A ^d   Hawkins, S A ^e   Billiau, A ^b   Dubois, B ^f   Weinshenker, B G ^a   Vandenbroeck, K ^c  

^a MAYO CLINIC   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^e ROYAL VICTORIA HOSPITAL   (United Kingdom)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Association; Gender; Interferon gamma (IFNG); Multiple sclerosis; Polymorphisms

Indexed keywords

ADENINE; CYTOSINE; DNA; GAMMA INTERFERON; GUANINE;

ADULT; ALLELE; ARTICLE; BELGIUM; CONTROLLED STUDY; DNA FLANKING REGION; ETHNIC GROUP; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY; HOSPITAL PATIENT; HUMAN; HUMAN CELL; INTRON; IRELAND; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; MULTIPLE SCLEROSIS; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

3' FLANKING REGION; ADULT; DINUCLEOTIDE REPEATS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERFERON TYPE II; INTRONS; LINKAGE (GENETICS); MALE; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX FACTORS;

EID: 20144387019     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6364164     Document Type: Article

References (80)

1. Oksenberg JR, Hauser SL. New insights into the immunogenetics of multiple sclerosis. Curr Opin Neurol 1997; 10: 181-185.
2. Dyment DA, Sadovnick AD, Ebers GC. Genetics of multiple sclerosis. Hum Mol Genet 1997; 6: 1693-1698.
3. Kantarci OH, de Andrade M, Weinshenker BG. Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 2002; 123: 144-159.
4. Ebers GC, Kukay K, Bulman DE et al. A full genome search in multiple sclerosis. Nat Genet 1996; 13: 472-476.
5. Haines J, Pericak-Vance M, Seboun E, Hauser S, and the Multiple Sclerosis Study Group. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. Nat Genet 1996; 13: 469-471.
6. Sawcer S, Jones HB, Feakes R et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996; 13: 464-468.
7. Kuokkanen S, Sundvall M, Terwilliger JD et al. A putative vulnerability locus to multiple sclerosis maps to 5p14-p12 in a region syntenic to the murine locus Eae2. Nat Genet 1996; 13: 477-480.
8. Chataway J, Feakes R, Coraddu F et al. The genetics of multiple sclerosis: principles, background and updated results of the United Kingdom systemic genome screen. Brain 1998; 121: 1869-1887.
9. Risch N, Merikangas KR. The future of genetic studies of complex human diseases. Science 1996; 273: 1516-1517.
10. Billiau A. Interferon-gamma in autoimmunity. Cytokine Growth Factor Rev 1996; 7: 25-34.
11. Navikas V, Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 1996; 45: 322-333.
12. Issazadeh S, Mustafa M, Ljungdahl A et al. Interferon gamma, interleukin 4 and transforming growth factor beta in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. J Neurosci Res 1995; 40: 579-590.
13. Renno T, Lin JY, Piccirillo C, Antel J, Owens T. Cytokine production by cells in cerebrospinal fluid during experimental allergic encephalomyelitis in SJL/J mice. J Neuroimmunol 1994; 49: 1-7.
14. Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 1996; 157: 3223-3227.
15. Espejo C, Penkowa M, Saez-Torres I et al. Treatment with anti-interferon-gamma monoclonal antibodies modifies experimental autoimmune encephalomyelitis in interferon-gamma receptor knockout mice. Exp Neurol 2001; 172: 460-468.
16. Horwitz MS, Evans CF, McGavern DB, Rodriguez M, Oldstone MB. Primary demyelination in transgenic mice expressing interferon-gamma. Nat Med 1997; 3: 1037-1041.
17. Renno T, Taupin V, Bourbonniere L et al. Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE. Mol Cell Neurosci 1998; 12: 376-389.
18. Popko B, Baerwald KD. Oligodendroglial response to the immune cytokine, interferon gamma. Neurochem Res 1999; 24: 331-338.
19. Kim IJ, Beck HN, Lein PJ, Higgins D. Interferon gamma induces retrograde dendritic retraction and inhibits synapse formation. J Neurosci 2002; 22: 4530-4539.
20. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988; 78 318-323.
21. Dettke M, Scheidt P, Prange H, Kirchner H. Correlation between interferon production and clinical disease activity in patients with multiple sclerosis. J Clin Immunol 1997, 17: 293-300.
22. Petereit HF, Nolden S, Schoppe S, Bamborschke S, Pukrop R, Heiss WD. Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients. Mult Scler 2002; 8: 492-494.
23. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1: 893-895.
24. Duquette P, Pleines J, Girard M, Charest L, Senecal-Quevillon M, Masse C. The increased susceptibility of women to multiple sclerosis. Can J Neurol Sci 1992; 19: 466-471.
25. Thompson AJ, Polman CH, Miller DH et al. Primary progressive multiple sclerosis. Brain 1997; 120 (Part 6): 1085-1096.
26. Pelfrey CM, Cotleur AC, Lee JC, Rudick RA. Sex differences in cytokine responses to myelin peptides in multiple sclerosis. J Neuroimmunol 2002; 130: 211-223.
27. Nguyen LT, Ramanathan M, Weinstock-Guttman B, Baier M, Brownscheidle C, Jacobs LD. Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients. J Neurol Sci 2003; 209: 93-99.
28. Zimonjic DB, Rezanka LJ, Evans CH, Polymeropoulos MH, Trent JM, Popescu NC. Mapping of the immune interferon gamma gene (IFNG) to chromosome band 12q14 by fluorescence in situ hybridization. Cytogenet Cell Genet 1995; 71: 247-248.
29. Giedraitis V, He B, Hillert J. Mutation screening of the interferon-gamma gene as a candidate gene for multiple sclerosis. Eur J Immunogenet 1999; 26: 257-259.
30. Ruiz-Linares A. Dinucleotide repeat polymorphisms in the interferon-gamma (IFNG) gene. Hum Mol Genet 1993; 2: 1508.
31. Wu S, Muhleman D, Comings DE. G5644A polymorphism in the interferon-gamma (IFNG) gene. Psychiatry Genet 1998; 8: 57.
32. Bream JH, Carrington M, O'Toole S et al. Polymorphisms of the human IFNG gene noncoding regions. Immunogenetics 2000; 51: 50-58.
33. Iwasaki H, Ota N, Nakajima T et al. Five novel single-nucleotide polymorphisms of human interferon gamma identified by sequencing the entire gene. J Hum Genet 2001; 46: 32-34.
34. Ackerman H, Udalova I, Hull J, Kwiatkowski D. Evolution of a polymorphic regulatory element in interferon-gamma through transposition and mutation. Mol Biol Evol 2002; 19: 884-890.
35. Bream JH, Ping A, Zhang X, Winkler C, Young HA. A single nucleotide polymorphism in the proximal IFN-gamma promoter alters control of gene transcription. Genes Immunity 2002; 3: 165-169.
36. Chevillard C, Henri S, Stefani F, Parzy D, Dessein A. Two new polymorphisms in the human interferon gamma (IFN-gamma) promoter. Eur J Immunogenet 2002; 29: 53-56.
37. He B, Xu C, Yang B, Landtblom AM, Fredrikson S, Hillert J. Linkage and association analysis of genes encoding cytokines and myelin proteins in multiple sclerosis. J Neuroimmunol 1998; 86: 13-19.
38. Vandenbroeck K, Opdenakker G, Goris A, Murru R, Billiau A, Marrosu MG. Interferon-gamma gene polymorphism-associated risk for multiple sclerosis in Sardinia. Ann Neurol 1998; 44: 841-842.
39. Goris A, Epplen C, Fiten P et al. Analysis of an IFN-gamma gene (IFNG) polymorphism in multiple sclerosis in Europe: effect of population structure on association with disease. J Interferon Cytokine Res 1999; 19: 1037-1046.
40. Reboul J, Mertens C, Levillayer F et al. Cytokines in genetic susceptibility to multiple sclerosis: a candidate gene approach. French Multiple Sclerosis Genetics Group. J Neuroimmunol 2000; 102: 107-112.
41. Dai Y, Masterman T, Huang WX et al. Analysis of an interferon-gamma gene dinucleotide-repeat polymorphism in Nordic multiple sclerosis patients. Mult Scler 2001; 7: 157-163.
42. Goris A, Heggarty S, Marrosu MG, Graham C, Billiau A, Vandenbroeck K. Linkage disequilibrium analysis of chromosome 12q14-15 in multiple sclerosis: delineation of a 118-kb interval around interferon-gamma (IFNG) that is involved in male vs female differential susceptibility. Genes Immun 2002; 3: 470-476.
43. Kantarci OH, Hebrink DD, Atkinson EJ, McMurray CT, Weinshenker BG. A comprehensive screen for genetic variation in the interferon-gamma gene in multiple sclerosis. Neurology 2000; 54 (Suppl 3): A324.
44. van Ooteghem P, D'Hooghe MB, Vlietinck R, Carton H. Prevalence of multiple sclerosis in Flanders, Belgium. Neuroepidemiology 1994; 13: 220-225.
45. Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology 2003; 61: 1373-1377.
46. McDonnell GV, Hawkins SA. An epidemiologic study of multiple sclerosis in Northern Ireland. Neurology 1998; 50: 423-428.
47. Marrosu MG, Murru MR, Costa G et al. Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA DR3 and DR4 alleles. Am J Hum Genet 1997; 61: 454-457.
48. Petrovsky N, Harrison LC. HLA class II-associated polymorphism of interferon-gamma production. Implications for HLA-disease association. Hum Immunol 1997; 53: 12-16.
49. Vandenbroeck K, Goris A. Cytokine gene polymorphisms in multifactorial diseases: gateways to novel targets for immunotherapy? Trends Pharmacol Sci 2003; 24: 284-289.
50. Dabora SL, Roberts P, Nieto A et al. Association between a high-expressing inteferon-gamma allele and a lower frequency of kidney angiomyolipomas in TSC2 patients. Am J Hum Genet 2002; 71 750-758.
51. Vandenbroeck K, Cunningham S, Goris A et al. Polymorphisms in the interferon-gamma/interleukin-26 gene region contribute to sex bias in susceptibility to rheumatoid arthritis. Arthritis Rheum 2003; 48: 2773-2778.
52. Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnot PJ, Hutchinson IV. In vitro production of IFN-γ correlates with CA repeat polymorphism in the human IFN-γ gene. Eur J Immunogenet 1999; 26: 1-3.
53. Hoffmann SC, Stanley EM, Cox ED et al. Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant 2002; 2: 560-567.
54. Hutchings A, Guay-Woodford L, Thomas JM et al. Association of cytokine single nucleotide polymorphisms with B7 costimulatory molecules in kidney allograft recipients. Pediatr Transplant 2002; 6: 69-77.
55. Miyake K, Nakashima H, Akahoshi M et al. Genetically determined interferon-gamma production influences the histological phenotype of lupus nephritis. Rheumatology 2002; 41: 518-524.
56. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsattelite marker of high IFN-gamma production. Hum Immunol 2000; 61: 863-866.
57. Lopez-Maderuelo D, Arnalich F, Serantes R et al. Interferon-gamma and interleukin-10 gene polymorphisms in pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 167: 970-975.
58. Rossouw M, Nel HJ, Cooke GS, van Helden PD, Hoal EG. Association between tuberculosis and a polymorphic NFkappaB binding site in the interferon gamma gene. Lancet 2003; 361: 1871-1872.
59. Young HA. Regulation of interferon-gamma gene expression. J Interferon Cytokine Res 1996; 16: 563-568.
60. O'Shea JJ, Paul WE. Regulation of T(H)1 differentiation - controlling the controllers. Nat Immunol 2002; 3: 506-508.
61. Martino G, Adorini L, Rieckmann P et al. Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurol 2002; 1: 499-509.
62. Fox HS, Bond BL, Parslow TG. Estrogen regulates the IFN-gamma promoter. J Immunol 1991; 146: 4362-4367.
63. Verthelyi D, Klinman DM. Sex hormone levels correlate with the activity of cytokine-secreting cells in vivo. Immunology 2000; 100: 384-390.
64. Sicotte NL, Liva SM, Klutch R et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 2002; 52: 421-428.
65. Kim S, Voskuhl RR. Decreased IL-12 production underlies the decreased ability of male lymph node cells to induce experimental autoimmune encephalomyelitis. J Immunol 1999; 162: 5561-5568.
66. Satoskar A, Al-Quassi HH, Alexander J. Sex-determined resistance against Leishmania mexicana is associated with the preferential induction of a Th1-like response and IFN-gamma production by female but not male DBA/2 mice. Immunol Cell Biol 1998; 76: 159-166.
67. Ishikawa R, Bigley NJ. Sex hormone modulation of interferon (IFN) alpha/beta and gamma production by mouse spleen cell subsets following picornavirus infection. Viral Immunol 1990; 3: 225-236.
68. McFarland HI, Bigley NJ. Sex-dependent, early cytokine production by NK-like spleen cells following infection with the D variant of encephalomyocarditis virus (EMCV-D). Viral Immunol 1989; 2 205-214.
69. Huygen K, Palfliet K. Strain variation in interferon gamma production of BCG-sensitized mice challenged with PPD II. Importance of one major autosomal locus and additional sexual influences. Cell Immunol 1984; 85: 75-81.
70. Dabora SL, Roberts P, Nieto A et al. Association between a high-expressing interferon-gamma allele and a lower frequency of kidney angiomyolipomas in TSC2 patients. Am J Hum Genet 2002; 71: 750-758.
71. Whitman SC, Ravisankar P, Daugherty A. IFN-gamma deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/- mice. J Interferon Cytokine Res 2002; 22: 661-670.
72. Han X, Lundberg P, Tanamachi B, Openshaw H, Longmate J, Cantin E. Gender influences herpes simplex virus type 1 infection in normal and gamma interferon-mutant mice. J Virol 2001; 75: 3048-3052.
73. Rodriguez M, Siva A, Ward J, Stolp-Smith K, O'Brien P, Kurland L. Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota. Neurology 1994; 44: 28-33.
74. Pittock SJ, Mayr WT, McClelland RL et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology 2004; 62: 51-59.
75. Kantarci OH, Hebrink DD, Achenbach SJ et al. A population-based association study of Fas and FasL polymorphisms in multiple sclerosis. J Neuroimmunol 2004; 146 162-170.
76. Goris A, Marrosu MG, Vandenbroeck K. Novel polymorphisms in the IL-10 related AK155 gene (chromosome 12q15). Genes Immun 2001; 2: 284-286.
77. Kwok PY. SNP genotyping with fluorescence polarization detection. Hum Mutat 2002; 19: 315-323.
78. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425-434.
79. SAS/STAT User's Guide, Version 8. SAS Institute Inc., Cary, NC, 1999.
80. InsightfulCorp. S-plus Reference Manual, Version 6. Seattle, WA, 2001.